Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 9/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.59 |
| ▸ | CASP6 | P55212 | 2/20 | 0.59 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.59 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.59 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21999978 | 0.86 | ACLY (0.74) | ACLYCTDSP1CASP6DUSP3PTPN5 | |
| SCHEMBL21999593 | 0.76 | ACLY (1.00) | ACLY | |
| SCHEMBL21930819 | 0.76 | ACLY (1.00) | ACLY | |
| SCHEMBL21999735 | 0.76 | ACLY (1.00) | ACLY | |
| SCHEMBL22000532 | 0.75 | ACLY (1.00) | ACLY | |
| SCHEMBL21999888 | 0.75 | ACLY (1.00) | ACLY | |
| SCHEMBL12659881 | 0.73 | MEN1 (0.73) | ACLYCTDSP1CASP6DUSP3PTPN5 | |
| SCHEMBL3911114 | 0.73 | L3MBTL1 (0.73) | ACLYCTDSP1CASP6DUSP3PTPN5 | |
| SCHEMBL22000630 | 0.73 | ACLY (0.77) | ACLY | |
| SCHEMBL3899468 | 0.73 | L3MBTL1 (1.00) | ACLYCTDSP1CASP6DUSP3PTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885CTDSP1 1033/4885CASP6 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.